Relevant bibliographies by topics / Ibogainas / Journal articles
To see the other types of publications on this topic, follow the link: Ibogainas.

Journal articles on the topic 'Ibogainas'

Author: Grafiati
Published: 4 June 2021
Last updated: 13 February 2022

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'Ibogainas.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Schellekens, A., T. Oosteren, T. Knuijver, R. J. verkes, and M. Belgers. "Treatment of heroin dependence with ibogaine." European Psychiatry 33, S1 (March 2016): S10—S11. http://dx.doi.org/10.1016/j.eurpsy.2016.01.799.

Full text
Abstract:
BackgroundThe use of the hallucinogen ibogaine as an anti-addiction agent has been described in several case reports, dating back to the eighties. The anti-addiction properties of ibogaine have been confirmed in a large body of animal work. Ibogaine has been shown to be effective in reducing withdrawal severity and substance use for a variety of substances, including cocaine and opiates. Animal studies also show some potentially dangerous adverse reactions, including cerebellar toxicity and potential cardiac effects. While pharmacological treatment options for opiate and cocaine dependence are still limited, ibogaine assisted treatment might be a promising new option. Therefore more systematic studies on its toxicity and efficacy are warranted. In our studies we address these two research questions: is ibogaine treatment for opiate dependence safe and effective for treating opiate withdrawal and relapse prevention? A secondary objective is to explore the pharmacokinetic properties of ibogaine.MethodsAnimal work: first we performed a systematic review and meta-analysis of animal studies on ibogaine. Thirty studies were included in the systematic review, of which 27 could be analyzed in meta-analysis. Human studies: fifteen opiate dependent patients will be treated with ibogaine (10 mg/kg), on top of treatment as usual. Ibogaine toxicity will be assessed through close monitoring with electrocardiography, with QTc prolongation as main outcome measure, repeated assessments of ataxia using the (SARA) and observation of psychotic symptoms by using the Delirium Observations Scale (DOS). Ibogaine efficacy will be measured, using repeated evaluations of opiate withdrawal severity (Subjective Opiate Withdrawal Scale: SOWS; Objective Opiate Withdrawal Scale: OOWS), craving intensity (using a Visual Analogue Scale) and substance use, with a six-month follow-up. Clinical observations in ibogaine treated individuals will be compared with a cohort of opiate dependent patients treated with a rapid detoxification procedure. Both acute and long-term effects will be linked with serum ibogaine and noribogaine levels.ResultsAnimal work: overall, ibogaine reduced drug self-administration, particularly during the first 24 hours after administration. Ibogaine had no effect on drug-induced conditioned place preference. Ibogaine administration resulted in motor impairment in the first 24 hours after supplementation, and cerebral cell loss even weeks after administration. Data on ibogaines effect on cardiac rhythm as well as on its neuropharmacological working mechanisms are limited. Human studies: human data are still being collected. Treatment of the first patients confirmed strong effects of ibogaine on heart rhythm (QTc prolongation) and ataxia, while the opiate withdrawal symptoms were relatively mild. The first observations on the clinical effect of ibogaine on craving and substance use will also be shared.ConclusionsBased on our meta-analysis of animal data, there is strong evidence that ibogaine is effective in reducing drug self-administration in animals. This warrants further studies into the clinical efficacy of ibogaine in substance dependent patients in reducing craving and substance use. Our first clinical experiences in a limited number of patients confirm that ibogaine treatment may be effective in reducing opiate withdrawal, but can potentially have transient cardiac and cerebellar toxicity.Disclosure of interestThe authors have not supplied his declaration of competing interest.
APA, Harvard, Vancouver, ISO, and other styles
2

Underwood, Martie S., Stephen J. Bright, and B. Les Lancaster. "A narrative review of the pharmacological, cultural and psychological literature on ibogaine." Journal of Psychedelic Studies 5, no. 1 (May 11, 2021): 44–54. http://dx.doi.org/10.1556/2054.2021.00152.

Full text
Abstract:
AbstractIbogaine is a psychoactive alkaloid contained in the West African plant Tabernanthe iboga. Although preliminary, evidence suggests that ibogaine could be effective in the treatment of certain substance use disorders, specifically opioid use disorder. This narrative review concentrated on the pharmacological, cultural and psychological aspects of ibogaine that contribute to its reputed effectiveness with a specific focus on the ibogaine state of consciousness. Although the exact pharmacological mechanisms for ibogaine are still speculative, the literature highlighted its role as an NMDA antagonist in the effective treatment of substance use disorders. The cultural aspects associated with the use of ibogaine pose questions around the worldview of participants as experienced in the traditional and western contexts, which future research should clarify. From a psychological perspective, the theory that the ibogaine state of consciousness resembles REM sleep is questionable due to evidence that indicated ibogaine supressed REM sleep, and contradictory evidence in relation to learning and memory. The suggested classification of the ibogaine experience as oneirophrenic also seems inadequate as it only describes the first phase of the ibogaine experience. The ibogaine experience does however present characteristics consistent with holotropic states of consciousness, and future research could focus on exploring and potentially classifying the state of consciousness induced by ibogaine as holotropic.
APA, Harvard, Vancouver, ISO, and other styles
3

Mačiulaitis, R., V. Kontrimavičiūtė, FMM Bressolle, and V. Briedis. "Ibogaine, an anti-addictive drug: pharmacology and time to go further in development. A narrative review." Human & Experimental Toxicology 27, no. 3 (March 2008): 181–94. http://dx.doi.org/10.1177/0960327107087802.

Full text
Abstract:
Ibogaine is an indole alkaloid derived from the bark of the root of the African shrub Tabernanthe iboga. Psychoactive properties of ibogaine have been known for decades. More recently, based on experimental data from animals and anectodal reports in human, it has been found that this drug has anti-addictive effects. Several patents were published between 1969 and 1995. The pharmacology of ibogaine is quite complex, affecting many different neurotransmitter systems simultaneously. However, the pharmacological targets underlying the physiological and psychological actions of ibogaine are not completely understood. Ibogaine is rapidly metabolized in the body in noribogaine. The purpose of this article was to review data from the literature concerning physicochemical properties, bio-analytical methods, and pharmacology of ibogaine; this article will be focused on the use of this drug as anti-addictive agent.
APA, Harvard, Vancouver, ISO, and other styles
4

Vidonja-Uzelac, Teodora, Nikola Tatalovic, Milica Mijovic, Gordana Kozelj, Aleksandra Nikolic-Kokic, Zorana Orescanin-Dusic, Mara Bresjanac, and Dusko Blagojevic. "Effects of ibogaine per os application on redox homeostasis in rat liver and erythrocytes." Archives of Biological Sciences 71, no. 1 (2019): 133–44. http://dx.doi.org/10.2298/abs180918055v.

Full text
Abstract:
Ibogaine, administered as a single oral dose (1-25 mg/kg body weight), has been used as an addiction-interrupting agent. Its effects persist for up to 72 h. Ex vivo results showed that ibogaine induced cellular energy consumption and restitution, followed by increased reactive oxygen species production and antioxidant activity. Therefore, the aim of this work was to explore the effect of a single oral dose of ibogaine (1 or 20 mg/kg body weight) on antioxidative defenses in rat liver and erythrocytes. Six and 24 h after ibogaine administration, histological examination showed glycogenolytic activity in hepatocytes, which was highest after 24 h in animals that received 20 mg/kg ibogaine. There were no changes in the activities of superoxide dismutases, catalase, glutathione peroxidase, glutathione reductase and glutathione-S-transferase in the liver and erythrocytes after ibogaine treatment, regardless of the dose. Hepatic xanthine oxidase activity was elevated in rats that received 20 mg/kg compared to the controls (p<0.01), suggesting faster adenosine turnover. TBARS concentration was elevated in the group treated with 1 mg/kg after 24 h compared to the controls (p<0.01), suggesting mild oxidative stress. Our results show that ibogaine treatment influenced hepatic redox homeostasis, but not sufficiently to remodel antioxidant enzyme activities at 6 and 24 h post-ibogaine application.
APA, Harvard, Vancouver, ISO, and other styles
5

Kubilienė, Asta, Rūta Marksienė, Saulius Kazlauskas, Ilona Sadauskienė, Almantas Ražukas, and Leonid Ivanov. "Acute toxicity of ibogaine and noribogaine." Medicina 44, no. 12 (September 28, 2008): 984. http://dx.doi.org/10.3390/medicina44120123.

Full text
Abstract:
Objective. To evaluate acute toxic effect of ibogaine and noribogaine on the survival of mice and determine median lethal doses of the substances mentioned. Material and methods. White laboratory mice were used for the experiments. Ibogaine and noribogaine were administered intragastrically to mice via a stomach tube. Control animals received the same volume of saline. The median lethal dose was calculated with the help of a standard formula. Results. To determine the median lethal dose of ibogaine, the doses of 100, 300, 400, and 500 mg/kg were administered intragastrically to mice. The survival time of mice after the drug administration was recorded, as well as the number of survived mice in each group. Upon administration of ibogaine at a dose of 500 mg/kg, all mice in this dose group died. Three out of four mice died in the group, which received 300 mg/kg of ibogaine. No mouse deaths were observed in the group, which received 100 mg/kg of ibogaine. The determined LD50 value of ibogaine equals to 263 mg/kg of body mass. In order to determine the median lethal dose of noribogaine, the doses of 300, 500, 700, and 900 mg/kg were administered to mice intragastrically. Noribogaine given at a dose of 500 mg/kg had no impact on the mouse survival. The increase of noribogaine dose to 700 mg/kg of mouse body mass led to the death of three out of four mice in the group. Upon administration of noribogaine at a dose of 900 mg/kg, all mice in this group died. The LD50 value of noribogaine in mice determined on the basis of the number of dead mice and the size of the doses used equals to 630 mg/kg of mouse body mass. The behavior of mice was observed upon administration of ibogaine or noribogaine. Low doses of ibogaine and noribogaine had no impact on the mouse behavior. External effects (convulsions, nervous behaviour, limb paralysis) were observed only when substances were administrated at higher doses. Conclusions. It has been determined that the median lethal dose of ibogaine and noribogaine equals to 263 mg and 630 mg/kg of mouse body mass, respectively. The toxicity of ibogaine is 2.4 times higher than that of noribogaine.
APA, Harvard, Vancouver, ISO, and other styles
6

Vidonja-Uzelac, Teodora, Nikola Tatalovic, Milica Mijovic, Aleksandra Nikolic-Kokic, Zorana Orescanin-Dusic, Mara Bresjanac, and Dusko Blagojevic. "Effects of ibogaine per os treatment on redox homeostasis in rat kidney." Archives of Biological Sciences 71, no. 2 (2019): 245–52. http://dx.doi.org/10.2298/abs190208006v.

Full text
Abstract:
Our previous results showed that a single oral dose (1 or 20 mg/kg body weight) of the anti-addiction agent ibogaine induced in rats 6 and 24 h after administration glycogenolytic activity in hepatocytes, followed by a mild oxidative stress. In this work, we examined the in vivo effect of the same doses of ibogaine on rat kidney morphology, antioxidant enzyme (superoxide dismutases (SOD1 and 2), catalase, glutathione peroxidase, glutathione reductase (GR) and glutathione- S-transferase) activities, and oxidative stress (TBARS) and redox (-SH groups) parameters. The dose of 1 mg/kg ibogaine induced an elevation in SOD1 activity and decreased GR activity after 6 and 24 h. GR activity was decreased at 6 and 24 h after 20 mg/kg ibogaine administration, suggesting changed redox homeostasis. After 24 h, we observed an increase in moderate morphological changes, without changes in urinalyses, indicating that kidney function was not measurably affected. Nevertheless, kidney-function monitoring during and following ibogaine use in human subjects is advisable.
APA, Harvard, Vancouver, ISO, and other styles
7

Oreščanin-Dušić, Zorana, Nikola Tatalović, Teodora Vidonja-Uzelac, Jelena Nestorov, Aleksandra Nikolić-Kokić, Ana Mijušković, Mihajlo Spasić, Roman Paškulin, Mara Bresjanac, and Duško Blagojević. "The Effects of Ibogaine on Uterine Smooth Muscle Contractions: Relation to the Activity of Antioxidant Enzymes." Oxidative Medicine and Cellular Longevity 2018 (2018): 1–10. http://dx.doi.org/10.1155/2018/5969486.

Full text
Abstract:
Ibogaine is an indole alkaloid originally extracted from the root bark of the African rainforest shrub Tabernanthe iboga. It has been explored as a treatment for substance abuse because it interrupts drug addiction and relieves withdrawal symptoms. However, it has been shown that ibogaine treatment leads to a sharp and transient fall in cellular ATP level followed by an increase of cellular respiration and ROS production. Since contractile tissues are sensitive to changes in the levels of ATP and ROS, here we investigated an ibogaine-mediated link between altered redox homeostasis and uterine contractile activity. We found that low concentrations of ibogaine stimulated contractile activity in spontaneously active uteri, but incremental increase of doses inhibited it. Inhibitory concentrations of ibogaine led to decreased SOD1 and elevated GSH-Px activity, but doses that completely inhibited contractions increased CAT activity. Western blot analyses showed that changes in enzyme activities were not due to elevated enzyme protein concentrations but posttranslational modifications. Changes in antioxidant enzyme activities point to a vast concentration-dependent increase in H2O2 level. Knowing that extracellular ATP stimulates isolated uterus contractility, while H2O2 has an inhibitory effect, this concentration-dependent stimulation/inhibition could be linked to ibogaine-related alterations in ATP level and redox homeostasis.
APA, Harvard, Vancouver, ISO, and other styles
8

Floresta, Giuseppe, Maria Dichiara, Davide Gentile, Orazio Prezzavento, Agostino Marrazzo, Antonio Rescifina, and Emanuele Amata. "Morphing of Ibogaine: A Successful Attempt into the Search for Sigma-2 Receptor Ligands." International Journal of Molecular Sciences 20, no. 3 (January 23, 2019): 488. http://dx.doi.org/10.3390/ijms20030488.

Full text
Abstract:
Ibogaine is a psychoactive indole alkaloid with high affinity for several targets including the σ2 receptor. Indeed, extensive data support the involvement of the σ2 receptor in neurological disorders, including Alzheimer’s disease, schizophrenia, alcohol abuse and pain. Due to its serious side effects which prevent ibogaine from potential clinical applications, novel ibogaine derivatives endowed with improved σ2 receptor affinity may be particularly beneficial. With the purpose to facilitate the investigation of iboga alkaloid derivatives which may serve as templates for the design of selective σ2 receptor ligands, here we report a deconstruction study on the ibogaine tricyclic moiety and a successive scaffold-hopping of the indole counterpart. A 3D-QSAR model has been applied to predict the σ2 pKi values of the new compounds, whereas a molecular docking study conducted upon the σ2 receptor built by homology modeling was used to further validate the best-scored molecules. We eventually evaluated pinoline, a carboline derivative, for σ2 receptor affinity through radioligand binding assay and the results confirmed the predicted high µM range of affinity and good selectivity. The obtained results could be helpful in the drug design process of new ibogaine simplified analogs with improved σ2 receptor binding capabilities.
APA, Harvard, Vancouver, ISO, and other styles
9

Wootton, Jacqueline C. "Ibogaine." Journal of Addictions Nursing 10, no. 3 (1998): 157–58. http://dx.doi.org/10.3109/10884609809041804.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

&NA;. "Ibogaine." Reactions Weekly &NA;, no. 1236 (January 2009): 21. http://dx.doi.org/10.2165/00128415-200912360-00061.

Full text
APA, Harvard, Vancouver, ISO, and other styles
11

&NA;. "Ibogaine." Reactions Weekly &NA;, no. 1399 (April 2012): 18. http://dx.doi.org/10.2165/00128415-201213990-00063.

Full text
APA, Harvard, Vancouver, ISO, and other styles
12

Popik, P., and S. D. Glick. "Ibogaine." Drugs of the Future 21, no. 11 (1996): 1109. http://dx.doi.org/10.1358/dof.1996.021.11.379472.

Full text
APA, Harvard, Vancouver, ISO, and other styles
13

Bethany Halford. "Taming ibogaine." C&EN Global Enterprise 98, no. 48 (December 21, 2020): 10. http://dx.doi.org/10.1021/cen-09848-scicon7.

Full text
APA, Harvard, Vancouver, ISO, and other styles
14

Mash, Deborah C., Barbara Ameer, Delphine Prou, John F. Howes, and Emeline L. Maillet. "Oral noribogaine shows high brain uptake and anti-withdrawal effects not associated with place preference in rodents." Journal of Psychopharmacology 30, no. 7 (April 4, 2016): 688–97. http://dx.doi.org/10.1177/0269881116641331.

Full text
Abstract:
This study investigated the effects of noribogaine, the principal metabolite of the drug ibogaine, on substance-related disorders. In the first experiment, mice chronically treated with morphine were subjected to naloxone-precipitated withdrawal two hours after oral administration of noribogaine. Oral noribogaine dose dependently decreased the global opiate withdrawal score by up to 88% of vehicle control with an ED50 of 13 mg/kg. In the second experiment, blood and brain levels of noribogaine showed a high brain penetration and a brain/blood ratio of 7±1 across all doses tested. In a third experiment, rats given oral noribogaine up to 100 mg/kg were tested for abuse liability using a standard biased conditioned place paradigm. Noribogaine-treated rats did not display place preference, suggesting that noribogaine is not perceived as a hedonic stimulus in rodents. Retrospective review of published studies assessing the efficacy of ibogaine on morphine withdrawal shows that the most likely cause of the discrepancies in the literature is the different routes of administration and time of testing following ibogaine administration. These results suggest that the metabolite noribogaine rather than the parent compound mediates the effects of ibogaine on blocking naloxone-precipitated withdrawal. Noribogaine may hold promise as a non-addicting alternative to standard opiate replacement therapies to transition patients to opiate abstinence.
APA, Harvard, Vancouver, ISO, and other styles
15

Jankowski, K., M. Delaforge, M. Jaouen, and H. Virelizier. "Oxidation of indolic bases by cytochrome P450 and ferrous picolinate." Spectroscopy 13, no. 2 (1997): 163–74. http://dx.doi.org/10.1155/1997/364081.

Full text
Abstract:
Oxidations performed on four indolic bases,β-carboline1, ibogaine2, reserpine3and ajmaline4, by hepatic cytochrome P450 (Cyt. P450) and ferrous picolinate (Fe(PA)2), lead to alicyclic hydroxylation as major reaction products.
APA, Harvard, Vancouver, ISO, and other styles
16

Jarraya, Raoudha Mezghani, Amira Bouaziz, Besma Hamdi, Abdelhamid Ben Salah, and Mohamed Damak. "N-(Hydroxymethyl)ibogaine." Acta Crystallographica Section E Structure Reports Online 64, no. 9 (August 9, 2008): o1739. http://dx.doi.org/10.1107/s1600536808025324.

Full text
APA, Harvard, Vancouver, ISO, and other styles
17

Soriano-García, M. "Structure of ibogaine." Acta Crystallographica Section C Crystal Structure Communications 48, no. 11 (November 15, 1992): 2055–57. http://dx.doi.org/10.1107/s0108270192002786.

Full text
APA, Harvard, Vancouver, ISO, and other styles
18

&NA;. "Ibogaine/various drugs." Reactions Weekly &NA;, no. 1418 (September 2012): 27–28. http://dx.doi.org/10.2165/00128415-201214180-00097.

Full text
APA, Harvard, Vancouver, ISO, and other styles
19

Zhang, Yuan-Wei, Benjamin E. Turk, and Gary Rudnick. "Control of serotonin transporter phosphorylation by conformational state." Proceedings of the National Academy of Sciences 113, no. 20 (May 2, 2016): E2776—E2783. http://dx.doi.org/10.1073/pnas.1603282113.

Full text
Abstract:
Serotonin transporter (SERT) is responsible for reuptake and recycling of 5-hydroxytryptamine (5-HT; serotonin) after its exocytotic release during neurotransmission. Mutations in human SERT are associated with psychiatric disorders and autism. Some of these mutations affect the regulation of SERT activity by cGMP-dependent phosphorylation. Here we provide direct evidence that this phosphorylation occurs at Thr276, predicted to lie near the cytoplasmic end of transmembrane helix 5 (TM5). Using membranes from HeLa cells expressing SERT and intact rat basophilic leukemia cells, we show that agents such as Na+ and cocaine that stabilize outward-open conformations of SERT decreased phosphorylation and agents that stabilize inward-open conformations (e.g., 5-HT, ibogaine) increased phosphorylation. The opposing effects of the inhibitors cocaine and ibogaine were each reversed by an excess of the other inhibitor. Inhibition of phosphorylation by Na+ and stimulation by ibogaine occurred at concentrations that induced outward opening and inward opening, respectively, as measured by the accessibility of cysteine residues in the extracellular and cytoplasmic permeation pathways, respectively. The results are consistent with a mechanism of SERT regulation that is activated by the transport of 5-HT, which increases the level of inward-open SERT and may lead to unwinding of the TM5 helix to allow phosphorylation.
APA, Harvard, Vancouver, ISO, and other styles
20

Pleskovic, Ales, Vojka Gorjup, M. Brvar, and G. Kozelj. "Ibogaine-associated ventricular tachyarrhythmias." Clinical Toxicology 50, no. 2 (February 2012): 157. http://dx.doi.org/10.3109/15563650.2011.647031.

Full text
APA, Harvard, Vancouver, ISO, and other styles
21

Litjens, Ruud P. W., and Tibor M. Brunt. "How toxic is ibogaine?" Clinical Toxicology 54, no. 4 (January 25, 2016): 297–302. http://dx.doi.org/10.3109/15563650.2016.1138226.

Full text
APA, Harvard, Vancouver, ISO, and other styles
22

&NA;. "Ibogaine neurotoxic in rodents." Reactions Weekly &NA;, no. 469 (September 1993): 4. http://dx.doi.org/10.2165/00128415-199304690-00014.

Full text
APA, Harvard, Vancouver, ISO, and other styles
23

Hayes, Gary. "Ibogaine ‐ poison or panacea?" Drugs and Alcohol Today 4, no. 3 (November 2004): 16–24. http://dx.doi.org/10.1108/17459265200400033.

Full text
APA, Harvard, Vancouver, ISO, and other styles
24

Alper, Kenneth R., Howard S. Lotsof, and Charles D. Kaplan. "The ibogaine medical subculture." Journal of Ethnopharmacology 115, no. 1 (January 2008): 9–24. http://dx.doi.org/10.1016/j.jep.2007.08.034.

Full text
APA, Harvard, Vancouver, ISO, and other styles
25

Yordanov, M., P. Dimitrova, S. Patkar, L. Saso, and N. Ivanovska. "Inhibition of Candida albicans extracellular enzyme activity by selected natural substances and their application inCandidainfection." Canadian Journal of Microbiology 54, no. 6 (June 2008): 435–40. http://dx.doi.org/10.1139/w08-029.

Full text
Abstract:
Extracellular enzymes secreted by Candida albicans are claimed to be virulence factors responsible for penetration of the yeast into host cells. Substances able to inhibit lipolytic and proteinase activities of the fungus might be of therapeutic use in some pathologic conditions caused by C. albicans. In the present work, we have tested the influence of the flavonoid compounds apigenin and kaempferol, the indole alkaloid ibogaine, and the protoberberine alkaloid berberine on the in vitro enzyme activity of C. albicans. The substances showed complex suppressive effects concerning the processes of adherence to epithelial cells, secreted aspartyl proteinase activity, and the rate of cell wall protein glycosylation. Apigenin and kaempferol were administered in systemic C. albicans infection, demonstrating an increased number of survivors by kaempferol. The application of apigenin, kaempferol, ibogaine, and berberine in cutaneous infection suppressed the symptoms and accelerated elimination of the yeast from the site of inoculation.
APA, Harvard, Vancouver, ISO, and other styles
26

Kohek, Maja, Maurice Ohren, Paul Hornby, Miguel Ángel Alcázar‐Córcoles, and José Carlos Bouso. "The Ibogaine Experience: A Qualitative Study on the Acute Subjective Effects of Ibogaine." Anthropology of Consciousness 31, no. 1 (March 2020): 91–119. http://dx.doi.org/10.1111/anoc.12119.

Full text
APA, Harvard, Vancouver, ISO, and other styles
27

Vlaanderen, L., L. C. Martial, E. J. F. Franssen, P. H. J. van der Voort, E. Oosterwerff, and G. A. Somsen. "Cardiac arrest after ibogaine ingestion." Clinical Toxicology 52, no. 6 (June 18, 2014): 642–43. http://dx.doi.org/10.3109/15563650.2014.927477.

Full text
APA, Harvard, Vancouver, ISO, and other styles
28

Asua, I. "Growing menace of ibogaine toxicity." British Journal of Anaesthesia 111, no. 6 (December 2013): 1029–30. http://dx.doi.org/10.1093/bja/aet396.

Full text
APA, Harvard, Vancouver, ISO, and other styles
29

Luciano, Daniel. "Observations on Treatment With Ibogaine." American Journal on Addictions 7, no. 1 (January 1998): 89. http://dx.doi.org/10.1111/j.1521-0391.1998.tb00472.x.

Full text
APA, Harvard, Vancouver, ISO, and other styles
30

Houenou, Josselin, Wided Homri, Marion Leboyer, and Noémie Drancourt. "Ibogaine-Associated Psychosis in Schizophrenia." Journal of Clinical Psychopharmacology 31, no. 5 (October 2011): 659. http://dx.doi.org/10.1097/jcp.0b013e31822c6509.

Full text
APA, Harvard, Vancouver, ISO, and other styles
31

Steinberg, Christian, and Marc W. Deyell. "Cardiac arrest after ibogaine intoxication." Journal of Arrhythmia 34, no. 4 (June 12, 2018): 455–57. http://dx.doi.org/10.1002/joa3.12061.

Full text
APA, Harvard, Vancouver, ISO, and other styles
32

SORIANO-GARCIA, M. "ChemInform Abstract: Structure of Ibogaine." ChemInform 24, no. 9 (August 20, 2010): no. http://dx.doi.org/10.1002/chin.199309238.

Full text
APA, Harvard, Vancouver, ISO, and other styles
33

Yip, Luke, and Jou-Fang Deng. "On the toxicity of ibogaine." Clinical Toxicology 54, no. 7 (May 31, 2016): 605. http://dx.doi.org/10.1080/15563650.2016.1190017.

Full text
APA, Harvard, Vancouver, ISO, and other styles
34

Paškulin, Roman, Polona Jamnik, Marko Živin, Peter Raspor, and Borut Štrukelj. "Ibogaine affects brain energy metabolism." European Journal of Pharmacology 552, no. 1-3 (December 2006): 11–14. http://dx.doi.org/10.1016/j.ejphar.2006.09.008.

Full text
APA, Harvard, Vancouver, ISO, and other styles
35

Molinari, H. H., I. M. Maisonneuve, and S. D. Glick. "Ibogaine neurotoxicity: a re-evaluation." Brain Research 737, no. 1-2 (October 1996): 255–62. http://dx.doi.org/10.1016/0006-8993(96)00739-1.

Full text
APA, Harvard, Vancouver, ISO, and other styles
36

French, Edward D., Kathryn Dillon, and Syed F. Ali. "Effects of ibogaine, and cocaine and morphine after ibogaine, on ventral tegmental dopamine neurons." Life Sciences 59, no. 12 (August 1996): PL199—PL205. http://dx.doi.org/10.1016/0024-3205(96)00412-2.

Full text
APA, Harvard, Vancouver, ISO, and other styles
37

GLICK, STANLEY D., and ISABELLE M. MAISONNEUVE. "Mechanisms of Antiaddictive Actions of Ibogainea." Annals of the New York Academy of Sciences 844, no. 1 (May 1998): 214–26. http://dx.doi.org/10.1111/j.1749-6632.1998.tb08237.x.

Full text
APA, Harvard, Vancouver, ISO, and other styles
38

Sessa, Ben, and Matthew W. Johnson. "Can psychedelic compounds play a part in drug dependence therapy?" British Journal of Psychiatry 206, no. 1 (January 2015): 1–3. http://dx.doi.org/10.1192/bjp.bp.114.148031.

Full text
Abstract:
SummaryAfter a 40-year hiatus there is now a revisiting of psychedelic drug therapy throughout psychiatry, with studies examining the drugs psilocybin, ketamine, ibogaine and ayahuasca in the treatment of drug dependence. Limitations to these therapies are both clinical and legal, but the possibility of improving outcomes for patients with substance dependency imposes an obligation to research this area.
APA, Harvard, Vancouver, ISO, and other styles
39

Mezamer, Sagit. "To the Roots: Me, My Brother, Heroin and Iboga." Journal of Extreme Anthropology 3, no. 2 (August 21, 2019): 184–95. http://dx.doi.org/10.5617/jea.7047.

Full text
Abstract:
In July 2018 we met at the airport, my brother and I. We were bound for Portugal, where my brother was about to undergo treatment for his heroin addiction. A visual essay following an Ibogaine treatment. By artist and curator, Sagit Mezamer The imagery in this essay is taken from drawings and photographs from Mezamer's new artwork - The Mother of Opium.
APA, Harvard, Vancouver, ISO, and other styles
40

Alper, Kenneth, Maarten E. A. Reith, and Henry Sershen. "Ibogaine and the inhibition of acetylcholinesterase." Journal of Ethnopharmacology 139, no. 3 (February 2012): 879–82. http://dx.doi.org/10.1016/j.jep.2011.12.006.

Full text
APA, Harvard, Vancouver, ISO, and other styles
41

Wasko, Michael J., Paula A. Witt-Enderby, and Christopher K. Surratt. "DARK Classics in Chemical Neuroscience: Ibogaine." ACS Chemical Neuroscience 9, no. 10 (September 14, 2018): 2475–83. http://dx.doi.org/10.1021/acschemneuro.8b00294.

Full text
APA, Harvard, Vancouver, ISO, and other styles
42

Touchette, Nancy. "Anti-addiction drug ibogaine on trial." Nature Medicine 1, no. 4 (April 1995): 288–89. http://dx.doi.org/10.1038/nm0495-288.

Full text
APA, Harvard, Vancouver, ISO, and other styles
43

Wolter Filho, Wilson, Carlos Humberto Souza Andrade, Raimundo Braz Filho, and Francisco José de Abreu Matos. "Alcalóides de Peschiera affinis (Muell. Arg) Miers (Apocynaceae)." Acta Amazonica 15, no. 1-2 (June 1985): 193–98. http://dx.doi.org/10.1590/1809-43921985152197.

Full text
Abstract:
A vista da discordância dos dados registrados na literatura (Cava, 1964, 1968 ; Jerry, 1963 e Matos, 1976) quanto aos alcalóides de Peschierra affinis, retomou-se seu estudo com o objetivo desta espécie. Foram analisados amostras das cascas e do lenho das raízes de material coletado em locais diferentes em altitude, longitude e latitude. Foram identificados além de substâncias de natureza alifática (sitosterol,β-amirina e lupenol). os seguintes alcalóides indólicos: coronaridina, voacangina, 20-epiheyneanina, voacristina, affinisina, vobasina, olivacina e uma mistura de 19-hidroxi-ibogamina e iboxigaína). Dentre estes, quatro são inéditos na espécie (voacangina, voacristina, 19-hidroxi-ibogaina e eboxigaína). Apenas pequenas diferenças foram observadas nos três materiais estudados, observando-se porém, acentuada diferença quando comparadas com os resultados obtidos no primeiro trabalho químico sobre os alcalóides desta espécie (Jerry, 1963).
APA, Harvard, Vancouver, ISO, and other styles
44

Pearl, S. M., L. B. Hough, D. L. Boyd, and S. D. Glick. "Sex Differences in Ibogaine Antagonism of Morphine-induced Locomotor Activity and in Ibogaine Brain Levels and Metabolism." Pharmacology Biochemistry and Behavior 57, no. 4 (August 1997): 809–15. http://dx.doi.org/10.1016/s0091-3057(96)00383-8.

Full text
APA, Harvard, Vancouver, ISO, and other styles
45

Brown, Thomas. "Ibogaine in the Treatment of Substance Dependence." Current Drug Abuse Reviews 6, no. 1 (June 1, 2013): 3–16. http://dx.doi.org/10.2174/15672050113109990001.

Full text
APA, Harvard, Vancouver, ISO, and other styles
46

Koja, Takeshi, Kouichiro Fukuzaki, Takeshi Kamenosono, Akira Nishimura, Ryoichi Nagata, and S, and E. Lukas. "Inhibition of Opioid Abstinent Phenomena by Ibogaine." Japanese Journal of Pharmacology 71 (1996): 89. http://dx.doi.org/10.1016/s0021-5198(19)36594-1.

Full text
APA, Harvard, Vancouver, ISO, and other styles
47

R. Alper, Howard S. Lotsof, Geerte, Kenneth. "Treatment of Acute Opioid Withdrawal with Ibogaine." American Journal on Addictions 8, no. 3 (January 1999): 234–42. http://dx.doi.org/10.1080/105504999305848.

Full text
APA, Harvard, Vancouver, ISO, and other styles
48

Brunt, Tibor M., and Ruud P. W. Litjens. "In reply – on the toxicity of ibogaine." Clinical Toxicology 54, no. 7 (May 31, 2016): 606. http://dx.doi.org/10.1080/15563650.2016.1190018.

Full text
APA, Harvard, Vancouver, ISO, and other styles
49

Yip, Luke, and Jou-Fang Deng. "On the relationship between ibogaine and noribogaine." Clinical Toxicology 56, no. 1 (July 6, 2017): 77. http://dx.doi.org/10.1080/15563650.2017.1339890.

Full text
APA, Harvard, Vancouver, ISO, and other styles
50

Parker, Linda A., Shepard Siegel, and Tracey Luxton. "Ibogaine attenuates morphine-induced conditioned place preference." Experimental and Clinical Psychopharmacology 3, no. 4 (1995): 344–48. http://dx.doi.org/10.1037/1064-1297.3.4.344.

Full text
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the bibliographies on the topic 'Ibogainas' for other source types:
Books
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography